Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon(European Bioinformatics Institute), Matthew D. Hellmann(AstraZeneca (United States)), Darwin Ye(Cancer Research Institute), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Ross Stewart(AstraZeneca (United Kingdom)), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Marta Łuksza(Institute for Advanced Study), Jingya Qiu(University of Pennsylvania), Kyung Jin Yoo(Lemuel Shattuck Hospital), Caroline G. McCarthy(Memorial Sloan Kettering Cancer Center), George Fromm(United Therapeutics (United States)), Divij Mathew(Parker Institute for Cancer Immunotherapy), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Jia Luo(Dana-Farber Cancer Institute), J. Carl Barrett(National Institute of Environmental Health Sciences), Mohamed Reda Keddar(AstraZeneca (United Kingdom)), Pedro Beltrão(SIB Swiss Institute of Bioinformatics), Mohsen Abu-Akeel(Swim Across America), Nicholas McGranahan(CRUK Lung Cancer Centre of Excellence), Jennifer L. Sauter(Memorial Sloan Kettering Cancer Center), Benjamin D. Greenbaum(Memorial Sloan Kettering Cancer Center), Andrew Chow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cailian Liu(Memorial Sloan Kettering Cancer Center), Ikbel Achour(AstraZeneca (United Kingdom)), Martin L. Miller(University of Cambridge), Xiang H.-F. Zhang(Baylor College of Medicine), Jayon Lihm(Memorial Sloan Kettering Cancer Center), Umesh Bhanot(Memorial Sloan Kettering Cancer Center), Chad Vanderbilt(Memorial Sloan Kettering Cancer Center), Andy J. Minn(Memorial Sloan Kettering Cancer Center), Taylor H. Schreiber(Nantucket Cottage Hospital), Jayalaksmi Miriyala(Lemuel Shattuck Hospital), Taha Merghoub(Cornell University)
Cited by 177
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k